Inlive®

Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive^®

Inlive^® is a preservative-free, Class I preventive biological product independently developed by SINOVAC, approved in December 2015 and launched in May 2016, for the prevention ofhand, foot and mouth disease (HFMD) caused by enterovirus type 71(EV71) in children aged 6–71 months.¹

Immunogenicity and Safety Supported by Scientific Evidence

Induced detectable antibody responses as early as 10 days after vaccination², with immune persistence lasting for at least five years³

In a Phase III age-expansion study, achieved a seroconversion rate of 95.5% in children aged 36–71 months, which was superior to that of the comparator vaccine and non-inferior to that observed in children aged 6–35 months⁴
Demonstrated good immunogenicity and safety when co-administered with other routine pediatric vaccines^5-7 and showed a favorable safety profile, with an incidence of adverse reactions of 1.079% in a multicenter study conducted in China⁸

Approved in Indonesia in November 2022.

Reference:

[1] Chinese Center for Disease Control and Prevention. Technical Guidelines for the Use of Inactivated Enterovirus 71 (EV71) Vaccine. 2016.

[2] Wang SY, et al. Hum Vaccin Immunother. 2020;16(7):1595-1601.

[3] Hu YM, et al. Hum Vaccin Immunother. 2018;14(6):1517-1523.

[4] Zhang LF, et al. J Pediatric Infect Dis Soc. 2021;10(4):440-447.

[5] Zhang ZW, et al. J Infect Dis. 2019;220(3):392-399.

[6] Liu X, et al. Hum Vaccin Immunother. 2021;17(12):5348-5354.

[7] Wu, L, et al. Hum Vaccin Immunother. 2024; 20(1)

[8] Zeng Ji, et al. Post-marketing multi-center safety surveillance of inactivated enterovirus A71 vaccine (Vero cell)

(For Reference Only by Medical and Pharmaceutical Professionals)